Рондомицин

Quick links

Choose a section

Quick links to important sections

Advertisements

Рондомицин

Advertisements
Advertisements

Overview of Рондомицин

Quick Facts

Property Description
Active Ingredient Metacycline hydrochloride
Form Oral Tablets
Pharmacological Class Tetracycline Antibiotic
General Purpose To halt the growth of bacterial infections
Origin Semisynthetic

What Type of Medicine is Рондомицин (Metacycline)?

Рондомицин is a prescription pharmaceutical containing the active substance Metacycline (Methacycline), which is classified as a semisynthetic antibiotic. It belongs to the tetracycline antibiotic class of medications. Metacycline is chemically synthesized as a modification of the natural compound Oxytetracycline, positioning it among the second-generation tetracyclines. This drug is valued for its broad-spectrum activity, meaning it is designed to target a diverse array of bacterial microorganisms in general scenarios requiring systemic antimicrobial intervention.

Composition and Form: The Active Ingredient and Its Form

The core of Рондомицин is the molecule Metacycline, typically formulated as the salt Metacycline hydrochloride. The preparation is manufactured as a single-component product, meaning its effect is derived entirely from the Metacycline molecule alone. The established route of administration is oral, with the drug commonly presented in a solid tablet dosage form for systemic delivery. The specific chemical structure of the compound allows the drug to effectively target systemic infections requiring sustained internal exposure.

What is the General Benefit of This Tetracycline Antibiotic?

The general therapeutic purpose of an antibiotic like Рондомицин is to stop the progression of bacterial infections. Metacycline achieves this by exerting a bacteriostatic effect, meaning its primary role is to inhibit the growth and reproduction of susceptible bacteria, rather than immediately destroying them. This mechanism provides time for the body’s own defenses to take over and clear the infection. By preventing the rapid increase in the bacterial population, the drug reduces the infectious burden, an action that assists the body's natural immune system in resolving the underlying infectious process.

Regulatory References

  1. National Institutes of Health DrugBank
Advertisements

What side effects are possible with Рондомицин?

Official Safety Profile and Adverse Reactions

The safety profile of Рондомицин (Metacycline), a tetracycline-class antibiotic, is primarily characterized by officially documented adverse reactions affecting several physiological systems, as defined in regulatory classifications.


Adverse Reaction Categories

Adverse effects are broadly classified by the organ systems they affect. Common or generally observed effects typically involve Gastrointestinal Disorders, such as nausea, vomiting, diarrhea, and glossitis (inflammation of the tongue). Skin and Subcutaneous Tissue Disorders, including maculopapular and erythematous rashes, are also listed.

Serious Adverse Reactions

Regulatory documents highlight specific, clinically significant reactions that are generally less frequent. These include Benign Intracranial Hypertension (pseudotumor cerebri), which usually resolves upon discontinuation, and the potential for C. difficile-associated diarrhea (CDAD), which can range in severity. Rare but documented events also include severe hypersensitivity reactions (e.g., anaphylaxis) and hepatic toxicity.


Population-Specific and Developmental Constraints

Explicit safety constraints exist for vulnerable populations. Use in pediatric patients (under 8 years) and pregnant individuals is associated with a risk of permanent tooth discoloration (yellow-gray-brown) and potential inhibition of linear skeletal growth rate during bone development. Additionally, patients with renal impairment face an increased risk of systemic drug accumulation and anti-anabolic effects, such as a rise in Blood Urea Nitrogen (BUN).

Key Safety Restrictions

The official labeling mandates certain restrictions due to known drug properties. Patients should avoid direct exposure to sunlight or ultraviolet light due to the risk of phototoxicity, which can manifest as an exaggerated sunburn reaction. Furthermore, the medicine carries a potential for the overgrowth of non-susceptible organisms (superinfections) during use.

Advertisements

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Рондомицин


Overdose Scope

Documented overdose presentations: Overdose may result in an increased incidence of side effects, or central nervous system manifestations such as headache and blurred vision associated with Pseudotumor Cerebri.

Physiological systems affected (as stated in label): Regulatory documentation notes risk to the Hepatic system (Hepatotoxicity, Liver Failure) and the Renal system (Azotemia, increased BUN, Acidosis) due to the drug's antianabolic action.

Dose-related or exposure-related factors (if applicable): The occurrence of Hepatotoxicity and Liver Failure is associated with large doses. Excessive systemic accumulation can also occur with usual doses in compromised patients.

Population-specific overdose notes (if applicable): In cases of renal impairment, lower total doses are indicated due to the risk of accumulation and resultant liver toxicity. In infants, high exposure may manifest as bulging fontanels.

Emergency-response statements (as written in official documents): Management consists of symptomatic and supportive treatment. The drug must be discontinued immediately if evidence of raised intracranial pressure is diagnosed.

When immediate medical help is required (label-derived phrasing only): Urgent medical attention is required for manifestations of severe outcomes, including signs indicative of Liver Failure or the development of raised intracranial pressure.


Overdose Classifications (High-Level)

Severity classification (as defined in official documents): The profile includes risk of severe and life-threatening outcomes such as Liver Failure and potential permanent visual sequelae.

Regulatory basis (EMA / FDA / etc.): Information is consistent with official overdose and toxicity sections of FDA Prescribing Information and EMA/National SmPCs for the Tetracycline class.

Overdose-context constraints (as defined in official documents): No specific antidote is known. The situation requires monitoring of Creatinine and BUN in high-risk patients.


Resulting Overdose Structure

Official overdose statements:

  • Overdose risk is tied to excessive systemic accumulation resulting in documented severe toxicities of the liver and kidneys.
  • Neurological presentations include headache, blurred vision, and bulging fontanels (in infants) as signs of elevated intracranial pressure.
  • Management is limited to symptomatic and supportive treatment, with mandatory discontinuation upon diagnosis of raised intracranial pressure.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents define the overdose profile of Metacycline primarily by linking excessive systemic accumulation to specific severe organ system toxicities in the liver and kidneys, alongside the risk of elevated intracranial pressure. This officially mandates that the presence of these severe clinical manifestations requires patients to seek immediate medical attention for procedural management, including required laboratory monitoring of hepatic and renal function, as stated in the prescribing information.

Advertisements

Therapeutic Uses of Рондомицин

The therapeutic utility of Рондомицин (Metacycline) is focused on providing support in managing conditions caused by susceptible bacteria. This supportive role is applied across multiple infectious domains and may assist with maintaining functional stability and easing discomfort.

The medication is commonly used to address conditions presenting with acute episodes in organ systems, including the lungs and airways (e.g., pneumonia, bronchitis), the urinary tract (pyelonephritis, cystitis), and specific infections caused by atypical or intracellular pathogens (e.g., Rickettsiae, Chlamydiae). It is also applied in contexts where additional symptomatic support is needed because the patient cannot tolerate other options, such as providing a broad-spectrum alternative for those with a penicillin allergy. The drug plays a role in managing groups of symptoms that may become intense or disruptive, such as fever, congestion, and localized inflammation.

“This supportive role is applied across multiple infectious domains, assisting with maintaining functional stability and easing discomfort.”

The medication contributes to easing the overall symptom load during acute or recurrent episodes.


Quick Fact: Support for Symptom Management Symptom Type Condition Category Primary Therapeutic Benefit
Symptoms related to systemic imbalance, Inflammation, Symptoms that interfere with daily functioning Conditions presenting with acute episodes, Inflammatory processes Contributes to easing the overall symptom load
Advertisements

Eligibility and Restrictions for Use

Eligibility for Рондомицин (Methacycline)

Official regulatory documents define strict limitations on who may use Рондомицин (Methacycline) based on hypersensitivity, age, and specific physiological states, primarily due to its classification as a tetracycline-class antibiotic.

Population Status Eligibility Rule (Official Basis)
Use is Contraindicated Persons with known hypersensitivity to Methacycline or any other tetracycline-class antibiotic.
Age Restriction Children under 8 years of age are generally restricted from use. This is due to the potential for permanent tooth discoloration (yellow-gray-brown) and enamel hypoplasia during tooth development.
Pregnancy Contraindicated in pregnancy, especially during the last half, as the drug can cross the placenta and affect fetal bone and tooth development, and carries a risk of maternal hepatotoxicity.
Lactation Generally not recommended. Because Methacycline is excreted in human milk, a decision must be made to either discontinue nursing or discontinue the medicine, based on the potential risk of effects on the nursing infant (e.g., dental or skeletal effects).
Condition-Specific Use is advised with particular caution in patients with renal impairment or hepatic dysfunction, as insufficient kidney function can lead to increased serum levels of the drug, potentially causing liver damage or aggravating a pre-existing state of kidney failure.

Connection to the overall eligibility profile: These constraints establish that Рондомицин is formally prohibited for individuals with a tetracycline allergy and for pregnant women. The restriction on children under eight years of age is mandatory unless the treating clinician determines the benefit outweighs the risk of permanent dental effects. Use in patients with kidney or liver issues requires special consideration and monitoring due to impaired clearance and increased risk of toxicity.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Metacycline, a tetracycline-class antibiotic, has documented interactions that primarily affect its absorption and may modify the effects of co-administered medicines, as detailed in official regulatory documents.

Exposure-Modifying Interactions

Certain substances must be separated from Metacycline administration due to a pharmacokinetic interaction where they impair the drug's oral absorption. This includes antacids containing aluminum, calcium, or magnesium, iron-containing preparations, and bismuth subsalicylate. These agents interfere with absorption by forming non-absorbable chelates, resulting in reduced systemic exposure and potentially decreased effectiveness. This absorption interference also applies to dairy products and calcium-rich foods, requiring a mandatory time separation for ingestion.

Pharmacodynamic and Prohibited Combinations

Official labeling defines several clinically significant interactions. The co-administration of Metacycline and systemic retinoids like Isotretinoin must be avoided due to the documented additive risk of Intracranial Hypertension. The concurrent use with Methoxyflurane is also strictly avoided due to reports of fatal renal toxicity. Metacycline may also depress plasma prothrombin activity, which necessitates the potential for a downward dosage adjustment of co-administered anticoagulant drugs (e.g., warfarin). Furthermore, concurrent use may render hormonal oral contraceptives less effective, and co-administration with Penicillins should be avoided due to interference with bactericidal action.

Advertisements

Mechanism of Action

Targeted Inhibition of Bacterial Protein Construction

The primary mechanism of Рондомицин (Metacycline) is to act as a reversible inhibitor by binding selectively to the 30S ribosomal subunit within susceptible bacteria. This binding causes steric obstruction at the A-site, which arrests the necessary binding of tRNA and effectively stops the process of peptide chain elongation. This molecular blockade leads to a bacteriostatic effect, preventing bacterial proliferation and thus resulting in the reduction of the bacterial population.


️ Secondary Modulation of Host Inflammatory Enzymes

Independent of its antibiotic function, the drug modulates host physiological systems by inhibiting certain matrix metalloproteinases (MMPs). This mechanism is relevant in pathways involving tissue-damaging responses. By reducing the activity of these enzymes, Рондомицин contributes to the modulation of specific inflammatory cascade pathways, which results in the altered activity of the host's physiological response.


Constraints on Mechanistic Efficacy

The drug's core mechanism is functionally constrained by bacterial defense systems. Resistance occurs when bacteria reduce the intracellular concentration of the drug through efflux pumps, or when the ribosomal target is protected by ribosomal protection proteins or structurally altered. This inability to reach or bind the 30S subunit prevents the essential protein synthesis arrest that defines the bacteriostatic effect.

Advertisements

Dosage and Administration Information

How to Use Рондомицин

Рондомицин (Metacycline hydrochloride) is administered via the oral route, typically formulated as a tablet or capsule for systemic delivery. The instructions for use are based on a divided daily schedule, where the total prescribed quantity is split into multiple doses taken across the day to ensure therapeutic levels are continuously maintained.

A crucial administration requirement involves taking the tablet swallowed whole with an adequate amount of fluid (e.g., a full glass of water). Patients are instructed to remain in an upright position following ingestion to prevent irritation of the esophagus.

Usage also requires managing co-administration. To avoid interference with drug absorption, intake must be separated from substances containing calcium, iron, or magnesium, such as dairy products and certain supplements. Treatment requires a minimum duration, generally continuing for at least 24 to 48 hours after all symptoms of the infection have subsided, ensuring a complete course of therapy.

Use is subject to specific constraints regarding the patient's age and organ function. The medicine is generally contraindicated for children under 8 years of age due to class-wide concerns regarding effects on developing bone and teeth. Furthermore, a mandatory reduction in the daily dosage or an extension of the dosing interval is required for patients with documented renal impairment to prevent excessive accumulation of the drug in the body.

Advertisements

Recent Clinical Evidence

Рондомицин: Recent Clinical Evidence

Evidence for Use in Acute Systemic Bacterial Infections

Research related to the medicine's use for bacterial infections has explored studies conducted through short-term, randomized controlled trials (RCTs). These studies, involving adult populations with acute infections (e.g., respiratory or skin), examined the tetracycline drug class it belongs to by comparing it against other established antibiotics. Studies monitored outcomes reflecting systemic resolution, such as clinical response rates and microbiological eradication. Findings from systematic reviews described how clinical response rates for the tetracycline class were measured in relation to comparison antibiotics evaluated in the same studies. However, specific evidence for Metacycline itself in recent large-scale trials remains limited, with research often focusing on other agents in the class.

Evidence for Adjunctive Support in Chronic Inflammatory Conditions

Research has also explored the use of the tetracycline class in contexts where non-antimicrobial properties are of interest for chronic conditions characterized by fluctuating symptoms and inflammation. RCTs and long-term observational settings, primarily involving adults with conditions like periodontitis, examined outcomes linked to inflammatory or irritative states. Findings described patterns observed in the studies related to changes measured in functional tissue markers when the drug was evaluated as an adjunct to mechanical cleaning. The evidence quality varies across studies, with research largely focused on the local delivery of other tetracycline-class members, limiting direct insight into the systemic oral tablet form of Рондомицин for this application.

Long-Term Studies and Follow-up Duration

Clinical trials typically focus on short-term symptom patterns relevant to acute treatment. Follow-up durations were limited in core efficacy trials, often concluding within a few weeks. While studies for chronic supportive conditions have monitored outcomes up to 12+ months, the long-term effects for the drug class are not fully established, and there is limited information regarding outcomes over extended periods following treatment.

Evidence in Specific Patient Populations

Clinical research generally focuses on broad adult populations, and the results apply only to the populations studied. Data for certain groups remain insufficient. For instance, few data are available for comprehensive subgroup findings in patients with multiple coexisting conditions (comorbidities). Comparative evidence is lacking specifically for Metacycline to distinguish its effect from other tetracyclines within demographics like older adults.

Key Studies & References Local administration of tetracyclines as an adjunct to subgingival scaling in chronic periodontitis: A systematic review and meta-analysis of randomized controlled trials. (Journal of Periodontology)

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Рондомицин (FAQ)

Q: What should one generally do if a scheduled dose of Рондомицин is missed?

Official patient information states that a missed dose is generally recommended to be taken as soon as it is remembered. However, if it is nearly time for the next scheduled dose, it is recommended that the dose be skipped. It is specified that a double dose must not be taken to make up for the one that was missed.

Q: What are the published guidelines regarding Рондомицин use in older adults (patients over 65)?

Regulatory documents advise that caution should be exercised when this medication is used in older adults. This is because age-related changes, particularly in kidney or liver function, may affect how the medicine is processed. Therefore, monitoring by a healthcare provider may be needed, and the labeling describes the potential need for a dosage adjustment.

Q: What happens in general if the full course of Рондомицин is not completed?

Official warnings emphasize the importance of completing the full course of therapy as prescribed. Stopping the medication too early, even if symptoms improve, is associated with risks of therapeutic failure, which includes recurrence or worsening of the infection. Incomplete treatment is also a factor that can contribute to the development of drug-resistant bacteria.

Q: What is the basic process for how Рондомицин is eliminated from the body?

According to the drug's pharmacokinetic information, Рондомицин is processed and concentrated by the liver in the bile. From there, the medicine is eliminated from the body primarily through both the urinary system and the feces.

Q: What is the maximum duration of treatment with Рондомицин typically cited in regulatory documents?

For most acute bacterial infections, official prescribing information suggests a treatment duration typically lasting between 7 and 28 days. While a minimum duration is often specified, a fixed maximum duration is not universally cited and depends on the specific condition being treated.

Q: What official warnings are associated with abrupt discontinuation of Рондомицин treatment?

Regulatory warnings mainly stress the need to complete the full treatment course as prescribed. The concern with abrupt discontinuation is the possibility of therapeutic failure, meaning the infection could return or be poorly treated, potentially fostering antibiotic resistance.

Q: Can Рондомицин be used to treat infections in tissues or organs other than the main indication?

Regulatory labeling indicates that Рондомицин is authorized for a range of systemic infections caused by susceptible microorganisms. These indications include various infections affecting the respiratory tract, as well as the skin and urinary tract, among others.

Q: How quickly does Рондомицин typically start acting in the body, based on research?

The drug is absorbed relatively quickly after oral intake, reaching its highest level in the bloodstream within a few hours. However, since the drug works by inhibiting bacterial growth (a bacteriostatic effect), the time required for symptoms to visibly improve may be longer than the time to peak concentration.

Q: Is there a general regulatory statement about alcohol consumption while on Рондомицин treatment?

Official information does not list a severe, life-threatening interaction between Рондомицин and alcohol. However, general safety guidance often advises against alcohol consumption during antibiotic use, as it can potentially worsen common side effects like dizziness and nausea, and may interfere with the body's healing process.

Q: Can Рондомицин affect blood sugar levels or interfere with diabetes monitoring?

While this is not listed as a common adverse reaction in the official product information, rare instances of low blood sugar (hypoglycemia) have been reported within the tetracycline class of antibiotics. Information regarding the possibility of this effect is available for patients with pre-existing conditions.

Q: Does Рондомицин carry a listed risk of dizziness or affect coordination?

The official labeling for this drug class reports that adverse reactions such as dizziness, lightheadedness, or a feeling of unsteadiness have occurred. Patients are cautioned to observe how the medicine affects them, particularly before engaging in tasks that require coordination.

Q: How is the general effectiveness of Рондомицин typically monitored by healthcare providers?

Monitoring of the drug's effectiveness is primarily achieved through clinical assessment, which involves observing whether the patient's symptoms of infection are resolving. In some situations, healthcare providers may utilize microbiological tests to confirm that the harmful bacteria have been eliminated.

Q: Is it listed that Рондомицин is associated with changes in mood or sleep patterns?

Official drug information for the tetracycline class mentions that side effects such as drowsiness or unusual sleepiness have been reported. These effects are generally less common than other adverse reactions, and changes in mood or other specific sleep patterns are not frequently cited.

Q: Where can a patient find reliable, official patient information leaflets for Рондомицин?

Reliable, official patient information leaflets, often called Medication Guides, are available directly from government sources. These documents are located on the websites of national regulatory agencies such as the FDA/DailyMed, the European Medicines Agency (EMA), or Health Canada.

Q: Does Рондомицин commonly cause headaches, based on clinical trial data?

Headache is a reported adverse reaction in the drug's safety profile, although it is generally less common compared to side effects affecting the gastrointestinal tract. Headache is also reported in association with a specific, rare serious adverse reaction (Benign Intracranial Hypertension).

Advertisements

How should Рондомицин be stored and disposed of?

Official Storage and Disposal Rules

Storage and disposal requirements for Рондомицин (Metacycline hydrochloride oral tablets) are governed by regulatory labeling to ensure product stability and public safety.

Storage Conditions

Requirement Official Instruction
Temperature Store at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F). Do not freeze.
Protection Keep protected from light and excessive moisture.
Container Store in the original, tightly closed, light-resistant container.
Safety Rule Always keep the medication out of the sight and reach of children.

Disposal Instructions

When disposing of unused or expired Рондомицин, official guidelines prohibit flushing it down the toilet or throwing it in household waste. The medicine must be returned to an authorized drug take-back location or collected via a pharmacy-based disposal program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Рондомицин found in:

A-Z Index: